• Explore /
  • Videos & Slides
  • / Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

Abstract Video & Slides

Presenter

Kohei Shitara

Kohei Shitara, MD

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Rapid Oral Abstract Session

Session Title

Rapid-Fire Abstract Session: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000011294

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 557)

DOI

10.1200/JCO.2018.36.4_suppl.557

Abstract #

557

Abstract Disclosures

Similar Videos & Slides

Speaker: Anthony B. El-Khoueiry, MD

Speaker: Yu Sunakawa, PhD

Speaker: J. Randolph Hecht, MD

Speaker: Akihito Tsuji, MD, PhD